Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1270250 | 0.81 | EGLN1 (0.45) | EGLN1KMT2A | |
| SCHEMBL1270239 | 0.79 | EGLN1 (0.73) | EGLN1 | |
| SCHEMBL12896201 | 0.76 | EGLN1 (0.57) | EGLN1KMT2ALMNAHPGD | |
| SCHEMBL1269068 | 0.73 | EGLN1 (0.45) | EGLN1EGFRPIM1PIM2 | |
| SCHEMBL1268890 | 0.70 | EGLN1 (0.69) | EGLN1 | |
| SCHEMBL1270094 | 0.68 | EGLN1 (0.45) | EGLN1KMT2AHPGD | |
| SCHEMBL3627966 | 0.67 | EGLN1 (0.43) | EGLN1 | |
| SCHEMBL1269157 | 0.67 | EGLN1 (0.47) | EGLN1KMT2AHPGD | |
| SCHEMBL1269880 | 0.67 | EGLN1 (0.76) | EGLN1 | |
| SCHEMBL1270563 | 0.67 | EGLN1 (0.67) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028507-A1 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2011-02-03 | — | — | US | claimed |
| US-20110028507-A1 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028507-A1 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | EGLN3, EGLN2, HIF1A | EGLN1 5/4885EGFR 2258/4885CLK1 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.